Occidental started with two growth narratives — the CrownRock acquisition and STRATOS carbon-capture technology — but weak oil prices, the sale of its chemicals division, and repeated technology delays pushed the company toward a far more defensive story built around debt repayment and cost discipline, culminating in a CEO transition after a decade of leadership.
The story
November 2023: two growth stories at once
On the Q3 2023 earnings call, CEO Vicki Hollub's voice carried no hesitation. She said the asset portfolio had "once again delivered record results in the hands of an exceptional team," and called the newly announced STRATOS carbon-capture partnership with BlackRock "a powerful signal to the market." The company had already deployed 60% of a $3 billion buyback program, and the chemicals division, OxyChem, was praised as impossible to overstate — carrying its own weight in results. STRATOS came with a specific promise attached: commercial operations by mid-2025.
Barely three months later, the story got rewritten
In December 2023, Occidental announced the $12 billion CrownRock acquisition, and its 10-K sprouted an entirely new risk factor — "Risks related to the CrownRock Acquisition" — mentioned 38 times. Debt rose again, and management drew a hard line: no share buybacks would resume until principal debt fell below $15 billion. 2024 went smoothly — CrownRock integration and record production — but in 2025, weakening oil prices and tariff issues combined to make the tone noticeably more defensive. On the Q1 2025 call, Hollub said, "We can't control the macro environment, but we can control how we respond to it," while simultaneously cutting capital spending and Delaware Basin rig count. Around the same time, OxyChem hit a Chinese oversupply-driven collapse in PVC and caustic-soda prices, triggering three consecutive quarters of guidance cuts.
The filing language shifted quietly, but clearly
From FY2021 through FY2024, the 10-K consistently referred to itself in the first person as "Occidental," but starting with the FY2025 10-K — filed after the OxyChem sale was announced — the filing switched to the third-person "the Company." "Climate change" mentions in the risk-factors section climbed steadily from 7 (FY2021) to 9 (FY2022) to 18 (FY2023), then fell to 16 (FY2024) before collapsing to just 2 mentions in FY2025. And the decades-old business subheading "CHEMICAL OPERATIONS" disappeared entirely from the FY2025 10-K's Business section — because OxyChem was no longer part of the company.
Today's leadership paints a very different future
Vicki Hollub stepped down as CEO effective June 1, 2026, succeeded by former COO Richard Jackson. His first earnings call skipped the "world-changing technology" narrative that STRATOS once carried, replacing it with a highly specific, conservative execution plan: generating an additional $4 billion in sustainable annual cash flow by 2030. The company explicitly stated it "no longer needs large-scale M&A," and capital-allocation priority number one is debt repayment (targets stepped down from $15 billion to $14.3 billion to $10 billion) and preparing for the 2029 preferred-stock redemption. Meanwhile, STRATOS — half of the 2023 story — has been pushed back twice from its original "mid-2025 commercial operations" promise to "operational conversion in 2027," and is now described by the company itself as a supplementary business that "needs a partner to move forward."
Guidance scorecard
| Promise (when made) | Actual result | Result |
|---|---|---|
| STRATOS commercial operations "mid-2025" | Phase 1 defect surfaced; full operations pushed to "2027 operational conversion" — an 18-24 month delay | Missed |
| OxyChem annual pretax income guidance (~$1.1B, early FY2024) | Cut three consecutive quarters ($1.1B → $1.0B → $0.9-1.0B → $0.8-0.9B), then the business was sold entirely — the biggest warning sign | Persistent miss → business divested |
| "Immediate 170K boe/d" production after CrownRock close | Delay acknowledged (Q2'24) due to well-mix differences; "170K+" reconfirmed by Q1'25 | Delayed, then met |
| $4.5B debt repayment within 12 months of CrownRock close | Achieved in about 7 months (Q3 2024) | Beat, ahead of schedule |
| $15B principal debt target (expected late 2026/early 2027) | Reached early (late 2025/early 2026) using OxyChem sale proceeds; targets then reset to $14.3B, then $10B | Beat, ahead of schedule |
| $4.5-6.0B in non-core asset sales (within 18 months of CrownRock close) | About $4.0B cumulative near the 18-month mark (Aug 2025) — close to the low end | Partially met |
| Quarterly production guidance | Beat the midpoint in most of 12 tracked quarters — suggests conservative guidance practice | Consistently beat |
| "Opportunistic, no formula" buyback policy | Analysts asked "why not formalize it" for at least 4 consecutive quarters; never adopted | Unresolved |
Of 8 tracked commitments, 3 were beaten or achieved ahead of schedule, 2 were persistently missed (one resulting in a full business divestiture), and 3 were delayed, partially met, or left unresolved. Financial and debt-related promises were almost always beaten, while large technology projects (STRATOS) and chemicals-segment forecasts repeatedly missed — a clear credibility gap between financial discipline and technology/business narratives.
Source: earnings call transcripts Q3-Q4 FY2023, Q1-Q4 FY2024, Q1-Q4 FY2025, Q1-Q2 FY2026.
Timeline
- Dec 2023CrownRock acquisition announced (~$12B); buybacks effectively paused pending debt below $15B.
- Aug 2024CrownRock acquisition closes; Ecopetrol stake-sale deal collapses amid Colombian presidential opposition.
- May 2025Tariffs and weak oil prices trigger the first defensive posture — capex and rig cuts, "we can't control the macro" language debuts.
- Nov 2025OxyChem sale to Berkshire Hathaway announced ($9.7B), framed as "the final milestone of a strategic transition."
- Jan 2026OxyChem sale closes — a decade-long "chemicals company" identity concludes; "Occidental" → "the Company" language shift follows.
- May 2026CEO Vicki Hollub's departure announced; STRATOS Phase 1 non-process equipment defect disclosed. Richard Jackson succeeds as CEO June 1; company adopts its first-ever crude oil hedging program.
- Aug 2026New CEO unveils a "$4 billion by 2030" cash-flow plan built on cost efficiency and debt repayment rather than growth; STRATOS full operations pushed to 2027.
Our read
Occidental's last three years read as a deliberate narrowing: from a company betting simultaneously on mega-M&A, carbon-capture technology leadership, and record chemicals earnings, to one built almost entirely around shale execution and debt discipline. The financial side of that story has consistently delivered — debt targets hit early, production usually beating guidance — while the technology and chemicals side has repeatedly disappointed. Under the new CEO, the open question is whether this narrower, more financial story is the company's permanent shape, or a transitional phase before growth ambitions return.
What we still don't know
- What exactly the STRATOS Phase 1 "non-process equipment defect" was and how much it cost to fix was never disclosed in detail, even through the Q2 2026 call.
- When and on what basis buybacks will be "formalized" under the new CEO — a question analysts have raised for four-plus consecutive quarters — remains unanswered.
- Whether enough cash will accumulate under prevailing oil prices to redeem the 2029 preferred stock is uncertain; the company itself has repeatedly said it "depends on the macro."
Frequently asked questions
Why did Occidental sell its chemicals business (OxyChem)?
OxyChem faced a Chinese-supply-driven price collapse in PVC and caustic soda that forced three consecutive quarters of guidance cuts through 2025. Occidental sold the division to Berkshire Hathaway for $9.7 billion in cash (closing January 2, 2026), using the proceeds to accelerate debt paydown and complete its shift to a pure oil-and-gas company.
Why did CEO Vicki Hollub step down?
Hollub, CEO for a decade, stepped down effective June 1, 2026, succeeded by former COO Richard Jackson. Her departure came as the company shifted its public narrative from growth-and-technology (large acquisitions, carbon capture) toward a far more conservative capital-discipline story centered on debt repayment.
What sources does this analysis draw from?
This piece is built from Occidental's 10-K filings for FY2021 through FY2025 and 12 quarters of earnings call transcripts from November 2023 to August 2026.